Our findings suggest that ALA/SFC could prevent the progression of obesity or T2DM-associated diseases such as diabetic nephropathy and NAFLD through enhancing mitochondrial activity and inducing HO-1 as an antioxidant. The gene discussed is HMOX1; the disease is metabolic dysfunction-associated steatotic liver disease.